Intracellular Historical Balance Sheet
ITCI Stock | USD 86.59 0.16 0.19% |
Trend analysis of Intracellular Th balance sheet accounts such as Total Current Liabilities of 129.7 M or Total Stockholder Equity of 366.2 M provides information on Intracellular's total assets, liabilities, and equity, which is the actual value of Intracellular Th to its prevalent stockholders. By breaking down trends over time using Intracellular balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Intracellular Th latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Intracellular Th is a good buy for the upcoming year.
Intracellular Inventory |
|
Intracellular |
About Intracellular Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Intracellular Th at a specified time, usually calculated after every quarter, six months, or one year. Intracellular Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Intracellular and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Intracellular currently owns. An asset can also be divided into two categories, current and non-current.
Intracellular Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Intracellular assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Intracellular Th books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from Intracellular's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Intracellular Th current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. As of now, Intracellular's Total Liabilities is increasing as compared to previous years. The Intracellular's current Property Plant Equipment is estimated to increase to about 3 M, while Total Assets are projected to decrease to under 410.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 37.9M | 63.7M | 108.5M | 113.9M | Total Assets | 489.9M | 754.8M | 728.3M | 410.9M |
Intracellular balance sheet Correlations
Click cells to compare fundamentals
Intracellular Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Intracellular balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 251.2M | 717.3M | 489.9M | 754.8M | 728.3M | 410.9M | |
Other Current Liab | 25.6M | 25.8M | 37.9M | 63.7M | 108.5M | 113.9M | |
Total Current Liabilities | 36.2M | 36.9M | 53.4M | 83.2M | 123.5M | 129.7M | |
Total Stockholder Equity | 195.0M | 656.9M | 417.9M | 656.1M | 591.4M | 366.2M | |
Accounts Payable | 7.4M | 5.5M | 8.7M | 10.4M | 11.5M | 6.4M | |
Cash | 107.6M | 60.0M | 92.4M | 148.6M | 147.8M | 74.0M | |
Other Assets | 608.1K | 350.7K | 86.1K | 86K | 98.9K | 94.0K | |
Common Stock Shares Outstanding | 55.2M | 70.4M | 81.3M | 94.0M | 95.9M | 55.1M | |
Short Term Investments | 116.4M | 597.4M | 320.0M | 443.3M | 350.2M | 287.1M | |
Other Current Assets | 6.3M | 15.6M | 26.8M | 46.9M | 42.4M | 44.6M | |
Total Liab | 56.2M | 60.5M | 72.0M | 98.7M | 136.9M | 143.7M | |
Common Stock | 5.6K | 8.0K | 8.2K | 9K | 10K | 6.6K | |
Property Plant Equipment | 2.3M | 2.0M | 22.6M | 1.9M | 2.2M | 3.0M | |
Net Tangible Assets | 195.0M | 656.9M | 417.9M | 656.1M | 754.5M | 792.2M | |
Property Plant And Equipment Net | 20.5M | 26.3M | 22.6M | 16.7M | 14.6M | 9.6M | |
Net Debt | (84.5M) | (30.9M) | (67.0M) | (128.6M) | (130.8M) | (124.3M) | |
Retained Earnings | (710.1M) | (937.1M) | (1.2B) | (1.5B) | (1.6B) | (1.5B) | |
Non Current Assets Total | 20.9M | 26.4M | 22.6M | 16.8M | 60.5M | 63.5M | |
Cash And Short Term Investments | 224.0M | 657.4M | 412.3M | 591.9M | 497.9M | 388.7M | |
Common Stock Total Equity | 5.6K | 8.0K | 8.2K | 9K | 10.4K | 5.5K | |
Retained Earnings Total Equity | (710.1M) | (937.1M) | (1.2B) | (1.5B) | (1.3B) | (1.3B) | |
Liabilities And Stockholders Equity | 251.2M | 717.3M | 489.9M | 754.8M | 728.3M | 443.0M | |
Non Current Liabilities Total | 20.0M | 23.6M | 18.7M | 15.5M | 13.3M | 10.0M | |
Capital Surpluse | 905.0M | 1.6B | 1.6B | 2.1B | 2.5B | 2.6B | |
Other Stockholder Equity | 905.0M | 1.6B | 1.6B | 2.1B | 2.2B | 2.3B | |
Property Plant And Equipment Gross | 20.5M | 26.3M | 1.8M | 1.9M | 14.6M | 15.3M | |
Total Current Assets | 230.3M | 690.9M | 467.3M | 738.0M | 667.8M | 428.9M | |
Accumulated Other Comprehensive Income | 128.3K | 480.6K | (363.7K) | (4.2M) | 104K | 109.2K | |
Net Invested Capital | 195.0M | 656.9M | 417.9M | 656.1M | 591.4M | 516.9M | |
Net Working Capital | 194.1M | 654.1M | 413.9M | 654.7M | 544.3M | 508.4M | |
Capital Stock | 5.6K | 8.0K | 8.2K | 9K | 10K | 8.5K |
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.